AbelZeta's C-CAR168 registrational Phase II trial in refractory Lupus Nephritis granted FDA clearance

argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102

AbelZeta's C-CAR168 receives EMA PRIME designation for Lupus Nephritis and Systemic Lupus Erythematosus

Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801

FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy

Lynk Pharmaceuticals completes patient enrolment for zemprocitinib Phase III clinical trial in ankylosing spondylitis

Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib

Antengene receives USD60m upfront payment from UCB

Teva and Polpharma Biologics enter global licensing agreement for biosimilar candidate to Ocrevus

United Therapeutics acquires Thymmune Therapeutics to expand regenerative cell therapy pipeline

AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata

AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo

Japan approves Wayrilz for immune thrombocytopenia treatment

Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026

Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19